News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Ian E. Krop

Articles by Ian E. Krop

8 Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple- Negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 Study

ByAditya Bardia, MD, MPH, FASCO,Ian E. Krop,Funda Meric-Bernstam, MD,Anthony W. Tolcher,Toru Mukohara,Aaron Lisberg,Toshio Shimizu,Erika P. Hamilton, MD,Alexander Spira, MD, PhD, FACP,Takahiro Kogawa

April 28th 2023

9 Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer

ByAditya Bardia, MD, MPH, FASCO,Ian E. Krop,Dejan Juric,Takahiro Kogawa,Erika P. Hamilton, MD,Alexander Spira, MD, PhD, FACP,Toru Mukohara,Takuya Tsunoda,Senthil Damodaran,Funda Meric-Bernstam, MD

April 28th 2023

Latest Updated Articles

Trending on CancerNetwork

Modifiable Risk Factors Suggest Potential for Improving Cancer Prevention

2026 Tandem Meetings: What’s the Latest Research in Multiple Myeloma?

Barriers to CAR T-Cell Referral and Center Access in Multiple Myeloma

Dato-DXd Receives Priority Review in Unresectable/Metastatic TNBC

Real World Outcomes of CAR T-Cell Therapy in Multiple Myeloma Including Older and Comorbid Patients